US 12,453,698 B2
Pharmaceutical biodissolvable gels for drug delivery
Shulin Ding, Silver Spring, MD (US); and Diane Tang-Liu, Las Vegas, NV (US)
Assigned to AIVIVA BIOPHARMA, INC., Las Vegas, NV (US)
Appl. No. 17/297,329
Filed by AIVIVA BIOPHARMA, INC., Las Vegas, NV (US)
PCT Filed Nov. 25, 2019, PCT No. PCT/US2019/063044
§ 371(c)(1), (2) Date May 26, 2021,
PCT Pub. No. WO2020/112655, PCT Pub. Date Jun. 4, 2020.
Claims priority of provisional application 62/771,529, filed on Nov. 26, 2018.
Prior Publication US 2022/0008336 A1, Jan. 13, 2022
Int. Cl. A61K 9/06 (2006.01); A61K 9/00 (2006.01); A61K 31/4439 (2006.01); A61K 31/47 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/20 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01)
CPC A61K 9/06 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0034 (2013.01); A61K 9/0048 (2013.01); A61K 31/4439 (2013.01); A61K 31/47 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01)] 19 Claims
 
1. A pharmaceutical composition comprising a reverse thermal gelation material, wherein the pharmaceutical composition makes a transition from liquid to gel near the body temperature of a mammal, and wherein the pharmaceutical composition further comprises an active pharmaceutical ingredient designed for anti-angiogenesis, wherein the active pharmaceutical ingredient comprises axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, pazopanib, or a combination thereof, and wherein the pharmaceutical composition comprises about 2% (w/w) to about 10% (w/w) methylcellulose, wherein the methylcellulose is methylcellulose A15LV.